GPR37 expression as a prognostic marker in gliomas: a bioinformatics-based analysis

Area of Science:

• Neuro-oncology
• Molecular Biology
• Immunology

Background:

• Gliomas are primary brain tumors with complex molecular alterations.
• GPR37, a G protein-coupled receptor (GPCR), is implicated in brain physiology and malignancies.
• Understanding GPR37's role in glioma is crucial for advancing treatment.

Purpose of the Study:

• To investigate the association between GPR37 gene expression and glioma's clinicopathological factors.
• To analyze GPR37's correlation with patient prognosis, immune cell infiltration, and methylation levels.
• To explore GPR37's potential as a diagnostic and prognostic biomarker in glioma.

Main Methods:

• Utilized TCGA, STRING, cBioPortal, TIMER, and MethSurv databases for comprehensive analysis.
• Employed ssGSEA algorithm to quantify immune cell infiltration, visualizing results with 'ggplot2'.
• Validated bioinformatics findings through immunohistochemical staining of clinical glioma samples.

Main Results:

• GPR37 expression was significantly upregulated in glioma tissues, correlating with poorer patient outcomes.
• GPR37 expression was linked to altered immune cell infiltration, including increased M2 macrophages and T cells.
• Hypomethylation of the GPR37 promoter was associated with high expression and poor prognosis in glioma patients.

Conclusions:

• GPR37 demonstrates significant diagnostic and prognostic value in glioma.
• GPR37's molecular functions provide novel insights into glioma's clinical diagnosis and treatment.
• Targeting GPR37 may represent a potential therapeutic strategy for glioma.